These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22299411)

  • 1. Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up.
    Desakorn V; Karmacharya BM; Thanachartwet V; Kyaw NL; Tansuphaswadikul S; Sahassananda D; Dhitavat J; Maek-a-nantawat W; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2011 Nov; 42(6):1414-22. PubMed ID: 22299411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
    Kiertiburanakul S; Khongnorasat S; Rattanasiri S; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):237-43. PubMed ID: 17375626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
    J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    Chokephaibulkit K; Plipat N; Cressey TR; Frederix K; Phongsamart W; Capparelli E; Kolladarungkri T; Vanprapar N
    AIDS; 2005 Sep; 19(14):1495-9. PubMed ID: 16135903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
    Saeng-aroon S; Tsuchiya N; Auwanit W; Ayuthaya PI; Pathipvanich P; Sawanpanyalert P; Rojanawiwat A; Kannagi M; Ariyoshi K; Sugiura W
    Antiviral Res; 2010 Jul; 87(1):22-9. PubMed ID: 20382184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    Vanprapar N; Cressey TR; Chokephaibulkit K; Muresan P; Plipat N; Sirisanthana V; Prasitsuebsai W; Hongsiriwan S; Chotpitayasunondh T; Eksaengsri A; Toye M; Smith ME; McIntosh K; Capparelli E; Yogev R;
    Pediatr Infect Dis J; 2010 Oct; 29(10):940-4. PubMed ID: 20453709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
    Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.